Drug intelligence / Profile preview

GIP(3-30)NH2

Development stage
Phase 2
Lead developer
Antag Therapeutics
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

GIP(3-30)NH2 is a truncated peptide fragment of the endogenous hormone gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide. It acts as a high-affinity, competitive antagonist of the human GIP receptor (GIPR). By binding to the GIP receptor without activating it, GIP(3-30)NH2 blocks the physiological actions of endogenous GIP—including stimulation of insulin secretion and other pancreatic hormones—making it a valuable tool for studying metabolic regulation and potential therapeutic target in metabolic diseases such as type 2 diabetes and obesity. The peptide is produced endogenously via DPP-4 cleavage of pro-GIP-derived peptides but can also be synthesized for research purposes[1][5][7][8].

Other names
gastric inhibitory polypeptide (3-30)-amideglucose-dependent insulin-releasing hormone(3-30) amide
02

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on GIP(3-30)NH2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIP(3-30)NH2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call